tradingkey.logo

Journey Medical Corp

DERM
查看詳細走勢圖
8.010USD
+0.140+1.78%
收盤 12/22, 16:00美東報價延遲15分鐘
211.24M總市值
虧損本益比TTM

Journey Medical Corp

8.010
+0.140+1.78%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+1.78%

5天

+4.03%

1月

+7.37%

6月

+23.04%

今年開始到現在

+104.86%

1年

+71.15%

查看詳細走勢圖

TradingKey Journey Medical Corp股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Journey Medical Corp當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在藥品行業排名67/158位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價13.50。中期看,股價處於上升通道。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Journey Medical Corp評分

相關信息

行業排名
67 / 158
全市場排名
172 / 4582
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 4 分析師
買入
評級
13.500
目標均價
+64.63%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Journey Medical Corp亮點

亮點風險
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.
業績增長期
公司處於發展階段,最新年度總收入56.13M美元
估值低估
公司最新PE估值-22.81,處於3年歷史低位
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉247.90K股
活躍度增加
近期活躍度增加,過去20天平均換手率0.31

Journey Medical Corp新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Journey Medical Corp簡介

Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.
公司代碼DERM
公司Journey Medical Corp
CEOMaraoui (Claude)
網址https://journeymedicalcorp.com/

常見問題

Journey Medical Corp(DERM)的當前股價是多少?

Journey Medical Corp(DERM)的當前股價是 8.010。

Journey Medical Corp 的股票代碼是什麼?

Journey Medical Corp的股票代碼是DERM。

Journey Medical Corp股票的52週最高點是多少?

Journey Medical Corp股票的52週最高點是9.400。

Journey Medical Corp股票的52週最低點是多少?

Journey Medical Corp股票的52週最低點是3.535。

Journey Medical Corp的市值是多少?

Journey Medical Corp的市值是211.24M。

Journey Medical Corp的淨利潤是多少?

Journey Medical Corp的淨利潤為-14.67M。

現在Journey Medical Corp(DERM)的股票是買入、持有還是賣出?

根據分析師評級,Journey Medical Corp(DERM)的總體評級為買入,目標價格為13.500。

Journey Medical Corp(DERM)股票的每股收益(EPS TTM)是多少

Journey Medical Corp(DERM)股票的每股收益(EPS TTM)是-0.345。
KeyAI